{"id":46386,"date":"2025-11-11T14:54:52","date_gmt":"2025-11-11T06:54:52","guid":{"rendered":"https:\/\/flcube.com\/?p=46386"},"modified":"2025-11-11T14:54:53","modified_gmt":"2025-11-11T06:54:53","slug":"lyell-immunopharma-secures-global-rights-to-lyl273-car%e2%80%91t-therapy-major-step-toward-mcrc-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=46386","title":{"rendered":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment"},"content":{"rendered":"\n<p><strong>Lyell Immunopharma, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LYEL:NASDAQ\">NASDAQ: LYEL<\/a>) announced the execution of a definitive licensing agreement with <strong>Innovative Cellular Therapeutics, Inc. (ICT)<\/strong>, a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains <strong>exclusive worldwide rights (outside Greater China)<\/strong> to develop, manufacture, and commercialize <strong>LYL273<\/strong> (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets <strong>Guanylate Cyclase\u202fC (GCC)<\/strong> for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-terms\">Deal Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Seller<\/strong><\/td><td>Innovative Cellular Therapeutics (ICT)<\/td><\/tr><tr><td><strong>Buyer<\/strong><\/td><td>Lyell Immunopharma (NASDAQ:\u202fLYEL)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>LYL273 \u2013 autologous GCC\u2011targeted CAR\u2011T<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global, <strong>excluding<\/strong> Greater China (mainland China, Hong\u202fKong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Up\u2011front Cash<\/strong><\/td><td><strong>USD\u202f40\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Equity Transfer<\/strong><\/td><td><strong>1.9\u202fmillion<\/strong> Lyell common shares (\u2248\u202fUSD\u202f22\u202fmillion at closing price)<\/td><\/tr><tr><td><strong>Potential Additional Cash<\/strong><\/td><td>\u2022 Clinical milestones: up to <strong>USD\u202f30\u202fmillion<\/strong><br>\u2022 Late\u2011stage regulatory milestones: up to <strong>USD\u202f115\u202fmillion<\/strong><br>\u2022 Commercial sales milestones: up to <strong>USD\u202f675\u202fmillion<\/strong><\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered royalty on net sales of LYL273 (terms confidential)<\/td><\/tr><tr><td><strong>Future Considerations<\/strong><\/td><td>Additional cash &amp; equity contingent on regulatory approvals and sales performance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lyl273-technology-snapshot\">LYL273 \u2013 Technology Snapshot<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target Antigen:<\/strong> Guanylate Cyclase\u202fC (GCC), highly expressed on colorectal adenocarcinoma cells and several other solid\u2011tumor subtypes.<\/li>\n\n\n\n<li><strong>CAR Design:<\/strong> Enhanced CD19 CAR backbone fused with a GCC\u2011specific scFv; engineered to <strong>boost CD19 CAR expression<\/strong> and <strong>modulate cytokine release<\/strong>, improving persistence in the immunosuppressive solid\u2011tumor microenvironment.<\/li>\n\n\n\n<li><strong>Mechanistic Advantages:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Improved Expansion:<\/strong> Optimized signaling domains promote robust in\u2011vivo proliferation.<\/li>\n\n\n\n<li><strong>Enhanced Infiltration:<\/strong> Modified chemokine receptors facilitate tumor\u2011site homing.<\/li>\n\n\n\n<li><strong>Controlled Cytokine Release:<\/strong> Reduces risk of cytokine\u2011release syndrome while maintaining cytotoxic potency.<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication Focus:<\/strong> Metastatic colorectal cancer (mCRC) and other GCC\u2011positive malignancies (e.g., gastric, pancreatic).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-amp-commercial-outlook\">Clinical &amp; Commercial Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Expected Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202f1\/2 Initiation<\/strong><\/td><td>Q2\u202f2026 (first\u2011in\u2011human dose escalation)<\/td><\/tr><tr><td><strong>Pivotal Trial Commencement<\/strong><\/td><td>H2\u202f2027 (global, multi\u2011center)<\/td><\/tr><tr><td><strong>Regulatory Submission (US FDA)<\/strong><\/td><td>Early\u202f2029 (assuming positive Phase\u202f2 data)<\/td><\/tr><tr><td><strong>Potential US Launch<\/strong><\/td><td>2029\u20112030, contingent on approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity:<\/strong> mCRC accounts for ~\u202f1.9\u202fmillion new cases worldwide annually; GCC expression is present in ~\u202f70\u202f% of colorectal tumors, representing a <strong>$12\u202fbillion<\/strong> addressable market in the United States alone.<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> The acquisition expands Lyell\u2019s pipeline beyond its existing CD19\u2011directed programs, positioning the company as a <strong>first\u2011to\u2011market GCC\u2011targeted CAR\u2011T<\/strong> developer.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the licensing transaction, clinical development timelines, regulatory expectations, and commercial potential of LYL273. Actual results may differ due to risks including clinical trial outcomes, regulatory approvals, manufacturing scale\u2011up, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative&#8230;<\/p>\n","protected":false},"author":1,"featured_media":46397,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3649,4448,4449],"class_list":["post-46386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-innovative-cellular-therapeutics","tag-lyell-immunopharma","tag-nasdaq-lyel"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=46386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment\" \/>\n<meta property=\"og:description\" content=\"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=46386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-11T06:54:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-11T06:54:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment\",\"datePublished\":\"2025-11-11T06:54:52+00:00\",\"dateModified\":\"2025-11-11T06:54:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386\"},\"wordCount\":416,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1112.webp\",\"keywords\":[\"Innovative Cellular Therapeutics\",\"Lyell Immunopharma\",\"NASDAQ: LYEL\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46386#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=46386\",\"name\":\"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1112.webp\",\"datePublished\":\"2025-11-11T06:54:52+00:00\",\"dateModified\":\"2025-11-11T06:54:53+00:00\",\"description\":\"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=46386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1112.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1112.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=46386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment - Insight, China&#039;s Pharmaceutical Industry","description":"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=46386","og_locale":"en_US","og_type":"article","og_title":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment","og_description":"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.","og_url":"https:\/\/flcube.com\/?p=46386","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-11T06:54:52+00:00","article_modified_time":"2025-11-11T06:54:53+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=46386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=46386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment","datePublished":"2025-11-11T06:54:52+00:00","dateModified":"2025-11-11T06:54:53+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=46386"},"wordCount":416,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=46386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","keywords":["Innovative Cellular Therapeutics","Lyell Immunopharma","NASDAQ: LYEL"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=46386#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=46386","url":"https:\/\/flcube.com\/?p=46386","name":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=46386#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=46386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","datePublished":"2025-11-11T06:54:52+00:00","dateModified":"2025-11-11T06:54:53+00:00","description":"Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative Cellular Therapeutics, Inc. (ICT), a Sino\u2011U.S. biotech venture. Under the deal, Lyell obtains exclusive worldwide rights (outside Greater China) to develop, manufacture, and commercialize LYL273 (formerly GCC19CART), an autologous CAR\u2011T cell candidate that targets Guanylate Cyclase\u202fC (GCC) for metastatic colorectal cancer (mCRC) and other GCC\u2011expressing solid tumors.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=46386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=46386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=46386#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","width":1080,"height":608,"caption":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=46386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lyell Immunopharma Secures Global Rights to LYL273 CAR\u2011T Therapy \u2013 Major Step Toward mCRC Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1112.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=46386"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46386\/revisions"}],"predecessor-version":[{"id":46398,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/46386\/revisions\/46398"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/46397"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=46386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=46386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=46386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}